Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 08, 2017. The document serves as a transaction notification regarding insider trading activities under Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transactions.
| Instrument | Transaction Date | Price per ADS | Volume |
|---|---|---|---|
| GlaxoSmithKline plc ADSs (ISIN: US37733W1053) | March 07, 2017 | $41.44 | 28 (Dr. M M Slaoui) |
| GlaxoSmithKline plc ADSs (ISIN: US37733W1053) | March 07, 2017 | $41.44 | 10 (Dr. K Slaoui) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document reports two separate increases in American Depositary Shares (ADSs) held by Persons Discharging Managerial Responsibilities (PDMR) and a Person Closely Associated (PCA).
- Dr. M M Slaoui (Chairman, Global Vaccines): Acquired 28 ADSs.
- Dr. K Slaoui (PCA of Dr. M M Slaoui): Acquired 10 ADSs.
Both transactions resulted from the revaluation of the cash element of notional investments within the GSK 401(K) plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of specific share allocations.
Investor Verification Points
- Verify the total number of ADSs held by Dr. M M Slaoui and Dr. K Slaoui following these allocations.
- Confirm the impact of the GSK 401(K) plan revaluation on other executive holdings.
- Note that this filing does not reflect broader company financial performance for the period.